• Valeant Pharmaceuticals – the rerating has only begun – target price $43

    July 16, 2017 | Posted by

    By Richard Jennings We last wrote about Valeant Pharmaceuticals HERE on March 7th 2017 in which we signed off with the comment – “We call it here “asymmetric skew” and at $11.56 given the points we have made re the debt profile and the likely attraction to industry players like Allergan (and a possible return […]

  • Silence Therapeutics – patent claim highlights multi million pound licence potential

    July 11, 2017 | Posted by

    By Richard Gill CFA In our initiation of coverage report on AIM listed RNA therapeutics specialist Silence Therapeutics (SLN) we highlighted the firm’s potentially valuable patent portfolio. Realising that value for shareholders might have come one step closer after the firm announced last week that it has issued a claim in the UK High Courts […]

  • Pricing Providence Resources going into the drill of 2017

    July 10, 2017 | Posted by

    By Richard Jennings  As the drill bit prepares to be turned on the South Porcupine basin offshore the South West coast of Ireland (licence known as FEL 2/14) we take a look at some potential share price implications (and suspend reservations that are well known on our part ref ToR Junior). The licence areas know […]

  • Obtala – Completion of WoodBois acquisition highlights further value potential

    July 3, 2017 | Posted by

    By Richard Gill, CFA Africa focussed forestry and agriculture company Obtala has announced three pieces of news to the market since last Friday afternoon. Most importantly, the company has finalised the previously announced acquisition of Gabon timber business Woodbois International through 75% owned forestry subsidiary Argento. The deal, which was completed by 30th June as […]